
Poxel Investor Relations Material
Latest events

H1 2023
Poxel

Q1 2025
13 May, 2025

H2 2024
19 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Poxel S.A.
Access all reports
Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases, particularly those related to metabolic disorders. The company's research pipeline includes treatments for conditions like non-alcoholic steatohepatitis (NASH) and rare metabolic diseases such as adrenoleukodystrophy (ALD). Poxel leverages proprietary platforms including adenosine monophosphate-activated protein kinase (AMPK) activators and deuterated thiazolidinedione (TZD) compounds. The company is headquartered in Lyon, France, with additional offices in Boston, Massachusetts, and Tokyo, Japan. Its shares are listed on Euronext Paris.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
POXEL
Country
🇫🇷 France